What are the key digital health trends in China? How does risk class classification for the NMPA (former CFDA) work? Are there any fast-track regulatory pathways? What are the latest updates regarding digital health regulations? We’ll answer all of these questions and more during our webinar with Cisema, a CRO and regulatory consultancy for China. Hamish King, Chief Operating Officer of Cisema, will present market opportunities and regulatory implications of the fast-growing digital health care sector in China. Join us on Tuesday, May 25 from 11:00 am - 12:00 pm ET to become better equipped to access China’s digital health market. Register now.
Agenda topics will include:
- Recent updates on the digital health care sector in China
- Regulatory pathways for medical devices and IVDs with the China National Medical Products Administration (NMPA, formerly CFDA)
- Cybersecurity updates
- SaMD registration in China
- Alternative regulatory pathways
Hamish King, Chief Operating Officer, Cisema
Hamish King is COO at Cisema, a China-focused CRO and regulatory consultancy founded in Munich and Beijing in 2002. A lawyer by training – admitted in Hong Kong and NSW, Australia – Hamish supports companies with difficult regulatory affairs queries for China. Formerly with UK Magic Circle Firm Linklaters in Hong Kong, he has nearly 10 years' experience in the legal and regulatory fields and has obtained the RAC and CFA qualifications. Regularly writing articles and speaking on China market access and regulatory pathways, he currently lives in Hong Kong and specializes in NMPA registration of medical devices. Hamish has a close interest in the regulatory implications of digital healthcare and AI applications.